At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- A Phase 2 Study of Belumosudil in People With Chronic Graft vs. Host Disease
Full Title Randomized Phase II study of belumosudil vs. placebo for preemptive treatment of chronic graft vs. host disease
Purpose
After a stem cell transplant, a condition called chronic graft-versus-host disease (cGVHD) can occur. The new donor immune cells (like T cells and B cells) attack the recipient’s healthy tissues, thinking they are foreign. It usually starts around 100 days after the transplant, but it can begin earlier or later.
The purpose of this study is to see if a medication called belumosudil can help prevent early cGVHD from getting worse. Researchers also hope that early treatment with belumosudil might help people avoid corticosteroids (like prednisone). Corticosteroids are commonly used to treat cGVHD, but they can have serious side effects.
Belumosudil helps control the immune system by blocking certain proteins involved in inflammation. This may help reduce or prevent damage caused by cGVHD. Belumosudil is taken by mouth.
If you join this study, you will be randomly assigned (like flipping a coin) to get either belumosudil or a placebo. A placebo is a pill with no active medicine. This helps researchers make a fair comparison between the treatment groups.
Who Can Join
To join this study, there are a few conditions. You must:
- Have cGVHD.
- Have not taken any immune-suppressing medication within 2 weeks of taking the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.
Protocol
25-004Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05996627ClinicalTrials.gov
-
Researchers are doing this study to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab is a safe treatment. They also want to know if receiving this combination treatment before surgery may allow patients to forgo the standard radiation treatment given after surgery.
-
The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:
-
Researchers are assessing a CAR T cell therapy to treat acute lymphoblastic leukemia (ALL) that keeps growing even with treatment. With CAR T cell therapy, some of your own T cells (a type of white blood cell) are removed. They are genetically modified (changed) in a lab to recognize your own cancer cells. The altered T cells, called CAR T cells, are then returned to your body to find and kill cancer cells. This treatment is a form of immunotherapy.
-
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
-
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
-
Researchers want to find the best dose of [AC-225]RTX-2358 to use safely in people with advanced sarcoma. The people in this study have sarcoma that has come back or keeps growing after treatment.
- A Phase 1-2 Study of BNT326 Alone or With BNT327 in People With Advanced Solid Tumors
Full Title A Phase I/II, Open-Label, Adaptive Two-Part trial to Evaluate the Safety, Efficacy, Optimal Dose, and Pharmacokinetics of BNT326 as Monotherapy and in Combination with Cancer Immunotherapies in Participants with Advanced Solid Tumors
Purpose
Researchers are assessing BNT326 alone or with BNT327 to treat advanced solid tumors. The people in this study have cancers that have come back or keep growing after treatment, including:
- Melanoma of the skin
-
Non-small cell lung cancer
- Bile duct cancer (cholangiocarcinoma)
- Liver cancer (hepatocellular carcinoma)
- Kidney cancer (renal cell carcinoma)
- Uterine (endometrial) cancer
- Pancreatic cancer
- Neuroendocrine cancer
- HER2-negative breast cancer
BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
BNT327 binds to one protein on the surface of cancer cells and another on the surface of immune cells. It may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. BNT327 is given intravenously. Only people with melanoma or breast cancer may be offered the combination of BNT326 and BNT327.
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the advanced cancers listed above.
- Have recovered from the serious side effects of prior treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.
Protocol
25-247Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07070232ClinicalTrials.gov
-
Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.
-
Researchers are assessing different doses of TNG462 to give with daraxonrasib or zoldonrasib in people with advanced cancer. The people in this study have pancreatic cancer or non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their cancers have a mutation (change) in the RAS gene and are missing a protein called MTAP.